Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding.
Authors:
- Truman J MillingTMTruman J Milling
- Jennifer FronteraJFJennifer Frontera
- 1 April 2017
- journal article
- Vol. 23, S67-S80
Abstract
Thrombosis is a leading cause of morbidity and mortality in the United States. Arterial and venous thromboses are implicated in the pathogenesis of major disorders, including myocardial infarction, ischemic stroke, and venous thromboembolism. Over the past decade, direct oral anticoagulants (DOACs) (eg, direct thrombin inhibitor and factor Xa [FXa] inhibitors) have been adopted as alternatives to warfarin due to their clinical advantages and efficacy for the treatment of thrombosis. As with all anticoagulants, treatment with DOACs is associated with a risk of major bleeding, including life-threatening gastrointestinal bleeds and intracranial hemorrhages (ICHs). In turn, the burden of bleeding associated with DOAC treatment is itself associated with substantial healthcare costs that are amplified by an increased risk of thromboembolic events and mortality following major bleeding events, especially in patients with ICHs. Given the rapid adoption of the DOACs and projected usage in the large patient population affected by thromboembolic conditions, clinicians are increasingly likely to encounter patients with major bleeding events due to DOAC therapy. Unlike warfarin, effective strategies to manage these bleeds are limited. There is an unmet need for reversal agents for use in the management of patients who receive FXa inhibitors and experience life-threatening bleeding or need emergency surgery. Andexanet alfa and ciraparantag are being evaluated as potential antidotes for both direct and indirect FXa inhibitors.Keywords
This publication has 71 references indexed in Scilit:
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)European Heart Journal, 2013
- Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical PatientsNew England Journal of Medicine, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Antithrombotic Therapy for Atrial FibrillationChest, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Thrombin Inhibitors from Different AnimalsJournal of Biomedicine and Biotechnology, 2010
- The story of the discovery of heparin and warfarinBritish Journal of Haematology, 2008
- Estimated annual numbers of US acute‐care hospital patients at risk for venous thromboembolismAmerican Journal of Hematology, 2007
- Investigations of the effects of ethanol on warfarin binding to human serum albuminJournal of Biomedical Science, 2000